DREAMM5
Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Filters
Save & Share
Clear Filters
Location
Explore options near your patient - or anywhere in the US.
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Near Add Your Location
Sorting 10 by
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
Dana-Farber Cancer Institute
Boston, MA
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
University of Alberta Hospital
Edmonton, AB
- Accepting patients
- Accepting patients
Queen Elizabeth II Health Sciences Centre
Halifax, NS
- Accepting patients
Scripps Green Hospital
San Diego, CA
- Not yet accepting
- Show Principal Investigator
- Not yet accepting
- Show Principal Investigator
1,350 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.